BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the addition of Holden Hodgson as Senior Managing Director, Derivatives. Mr. Hodgson will be based in the ...

Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...

Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Fintel reports that on November 7, 2024, Leerink Partners upgraded their outlook for Zymeworks (NasdaqGS:ZYME) from Market ...

Industry Veterans Grant Curry and Jason Truman Join Leerink Partners. BOSTON, Nov. 14, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, announced today ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

In a report released on November 11, Roanna Ruiz from Leerink Partners maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report). The company’s shares closed yesterday at $16.61.

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) yesterday. The company’s shares closed yesterday at $60.46. According to TipRanks, Berens is an ...